Sponsored by NIH Grant Number: 5U01AI066560
  • Home
  • About Us
    • About CoFAR
    • Food Allergy Education Program
    • Project Bibliography
    • Contact A Site
  • Resources
    • Project
    • Protocol
  • Publications
    • Abstracts, Articles and Presentations
  • Conference Call/Meetings
  • Data Entry
  • AADCRC

About Us

The Consortium of Food Allergy Research (CoFAR) was established in July 2005 by the National Institute of Allergy and Infectious Diseases (NIAID) to conduct both observational and clinical studies to answer questions related to food allergies.

A food allergy is an immunological disease that is responsible for substantial morbidity and mortality. Food allergies occur in 6 ­ 8% of children and 2% of adults, and prevalence is increasing. Severe food allergic reactions may cause anaphylaxis and/or death.

CoFAR Studies
Recent advances in food allergy research suggest that the direction of new, focused research will advance our understanding of the pathophysiology of food allergies and translate these findings into new options for identification and treatment of susceptible individuals.

In July 2006, we began enrollment into our first study which is an observational study of food allergy. The study is researching the development of peanut allergy in infants (3 to 15 months in age) with known milk or egg allergy. This study is closed to enrollment.

A second study, Egg Oral Immunotherapy, was opened in July 2007.  This 2 year treatment study is investigating the outcome in egg allergic individuals (6 to 18 years) who receive a powdered egg product or placebo by mouth. This study is closed to enrollment.

A third study, Peanut Sublingual Immunotherapy, was opened in April 2008.  This 4 year treatment study is investigating the outcome in peanut allergic individuals (12-40 years) who receive a liquid peanut product or placebo under the tongue.This study is closed to enrollment.

A fourth study, EMP-123, was opened in March 2009. This is a 7 month first in human Phase I trial investigating the safety and possible side effects of a peanut vaccine in healthy volunteers first and then in peanut allergic subjects (18-40 years).This study is closed to enrollment.

A fifth study, Eosinophilic Esophagitis Databank, was opened in April 2011.  This is a one visit  study, collecting blood and medical history.  The purpose is to investigate the genetic components of  Eosinophilc Esophagitis  through  multiple genetic  analysese  in  subjects  6 months old  through 65 years.  This study is open for enrollment.

Interested families can get more information by contacting a Study Coordinator at a participating site: Contact Us

Additional studies are being planned, so please check back in the future for updates.

Dr. Hugh Sampson, Mount Sinai Medical Center, Jaffe Food Allergy Institute, is the Clinical Project Leader for the Consortium. Other participating sites include (for contact information, go to Contact a Site):
Duke University Medical Center
Johns Hopkins University
National Jewish Health
University of Arkansas for Medical Sciences